Atazanavir for HIV Infected Individuals: An Early Access Program

• Conditions: HIV Infections

• Registration Number: NCT00046345
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this clinical research study is to provide atazanavir to patients infected with human immunodeficiency virus (HIV) whose antiviral medications are no longer working to control HIV activity within the body and who are unable to create a new treatment regimen using other available anti-HIV drugs, because of either side effects or treatment failure previously taken. The safety of this treatment will also be studied.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Study First Submitted: 2002-09-26
• Study First Submitted QC: 2002-09-27
• Study First Posted: 2002-09-30
• Study Completion: 2003-07
• Status Verified: 2011-04
• Last Update Submitted: 2011-04-13
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: NO_LONGER_AVAILABLE
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: EXPANDED_ACCESS
• Study Design: Not specified

Trial Locations

Locations (4)

LOcal Instituton; 🇺🇸 Sarasota, Florida, United States

Local Institution; 🇵🇷 Rio Piedras, Puerto Rico

local Institution; 🇺🇸 Fairfax, Virginia, United States

Local Instituton; 🇺🇸 Westfield, New Jersey, United States